Chapter 12: Problem 11
Stevia Sweetener Stevia is a leafy green plant native to subtropical and tropical regions (http://en.wikipedia.org/wiki/Stevia). It is grown around the world for its sweet leaves, which are used in a variety of forms as a high- intensity sweetener. Stevia extracts have \(200-300\) times the sweetness of sucrose and do not raise blood glucose. Stevia-based sweeteners are used today in dairy products, health drinks and carbonated beverages. Both Coca Cola and PepsiCo have introduced drinks containing stevia-based sweeteners under the commercial names of Truvia and PureVia, respectively. Stevia sweeteners are presently extracted from the leaves of stevia plants. However, recent advances in synthetic biology have enabled the production of stevia sweeteners via fermentation. Based on information from the technical and patent literature, design and evaluate a fermentation process for producing \(5,000,000 \mathrm{~kg}\) of stevia sweeteners per year for applications in the beverage industries. Assume that production is accomplished via fermentation in yeast that secretes stevia molecules, reaching a product titer in the fermentation broth of \(75 \mathrm{~g} / \mathrm{liter}\). The purification train includes a disk-stack centrifuge for biomass removal and a sequence of chromatography, membrane filtration, crystallization, and drying units for the isolation and purification of the product. Your analysis should include overall material and energy balances, equipment sizing, and estimation of capital and operating cost. Furthermore, estimate the profitability of the investment assuming a selling price for the final product equal to 200 times the current price of sucrose. 12 MAb Production in Stirred Tank Bioreactors with Disposable Bags The MAb example in section \(12.6 .3\) analyzes a process for producing \(1,544 \mathrm{~kg}\) of purified MAb per year using four 20,000 liter stainless steel production bioreactors operating in staggered mode (out of phase) and feeding a single purification train. The product titer is 2 \(\mathrm{g} / \mathrm{liter}\) and the cycle time of each bioreactor is 2 weeks. In the last few years, new cell lines have become available (e.g., PER.C6 from Percivia) that can reach significantly higher product titers ( > \(20 \mathrm{~g} / \mathrm{liter}\) ). Deployment of such cell lines greatly reduces the volume of the upstream equipment and enables single-use systems to produce metric ton quantities of MAbs. Rocking and stirred tank bioreactors that utilize single- use (disposable) liners (bags) have become popular in the biopharmaceutical industry because they eliminate the need for cleaning and sterilization-in- place. Other advantages of such systems include increased processing flexibility and shorter validation, start-up, and commercialization times. Single-use bioreactors are available with working volume of up to 2,000 liters. Design a process using the new technologies described above which can produce \(1,200 \mathrm{~kg}\) of a therapeutic monoclonal antibody per year. Assume you make use of the PER.C6 cell line that can consistently reach \(10 \mathrm{~g} / \mathrm{liter}\) of product titer. For product purification, assume that you need two adsorptive chromatography steps (e.g., affinity and hydrophobic interaction) followed by a polishing ion exchange membrane adsorber that operates in flow-through mode (the product flows through the unit but certain DNA and other charged impurity molecules are retained by the membrane). Your analysis should include overall material and energy balances, equipment sizing, and estimation of capital and operating costs.
Short Answer
Step by step solution
Key Concepts
These are the key concepts you need to understand to accurately answer the question.